Read this tip to make your life smarter, better, faster and wiser. LifeTips is the place to go when you need to know about Case Against Bextra and other Bextra topics.
More than 10 million people were using a COX-2 anti-inflammatory drug on Sept. 30, 2004, when Merck announced Vioxx's withdrawal, followed by a suspension of sales of Bextra by Pfizer. In 2003, Vioxx, Celebrex, and Bextra reaped more than $6 billion in sales, driven by $400 million in advertising targeting doctors and consumers. These sales were driven by claims that COX-2 anti-inflammatory drugs were safer than older NSAIDs such as Motrin, Voltaren, and Naprosyn; claims that have still not convinced many experts, especially in light of recent new studies.